Compare AbbVie Inc (ABBV) vs Colgate-Palmolive Company (CL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Colgate-Palmolive Company — how do they compare? AbbVie Inc trades at $254.52 (market cap $449.91B), while Colgate-Palmolive Company trades at $93.5 (market cap $76.04B). The key difference: AbbVie Inc is far larger — about 5.9× Colgate-Palmolive Company's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | CL | |
|---|---|---|
Market Cap | $449.91B | $76.04B |
Sector | Health | Consumer Staples |
52-Week High | $261.07 | $99.14 |
52-Week Low | $184.85 | $74.98 |
Enterprise Value | $513.38B | $82.68B |
Dividend Yield | 2.72% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.63, down 0.84% on the day, with a bullish technical signal and strong support at $248. The stock shows robust fundamentals with revenue growth to $61.16B in 2025 and consistent earnings beats, though net margins have compressed to 5.79%. Recent news highlights positive Phase 2 trial data for ELAHERE in ovarian cancer and institutional accumulation, reinforcing growth prospects beyond Humira's patent expiry.
Outlook remains positive with a consensus price target of $266.33 (5.4% upside), supported by 68% analyst buy ratings. Key opportunities include immunology drugs Skyrizi and Rinvoq driving growth, but risks involve patent cliffs in the 2030s, high debt levels, and regulatory pressures on drug pricing. The stock offers a resilient dividend with recent increases, appealing for income-focused investors amid sector volatility.
Colgate-Palmolive (CL) trades at $95.03, down 0.11% on the day, with a bullish technical outlook supported by moving averages and recent earnings beats. The company maintains strong profitability with a 60.06% gross margin and 10.04% net margin, though its P/E of 36.2 and P/B of 515.38 reflect premium valuation. Positive sentiment is driven by dividend consistency and strategic growth initiatives, while cash flow trends show stable operational performance.
Outlook remains cautiously optimistic with analyst consensus at Buy 42%, Hold 53%, and a $95.50 price target. Key opportunities include international growth and pricing power, but risks involve North American softness and high valuation multiples. The stock's 17% YTD gain underscores resilience, though inflation and competitive pressures warrant monitoring for sustained outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →
